Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoluminal HDR Brachytherapy with Concurrent Chemotherapy for Recurrent Rectal or Anal Cancer
NCT02199236Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2014
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jul 2014; status: completed.
Beyond the preview
Go deeper on NCT02199236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199236.